Undisclosed foreign asset classification requires an unexplained source; unrebutted affidavits and corroborative evidence defeated the Black Money Act...
Specialized Investment Fund distribution now requires dedicated certification, while transitional recognition preserves existing qualified distributor...
Bulk drugs and active pharmaceutical ingredients imported under Chapters 28 or 29 qualify as drugs because they are substances used as components of pharmaceutical products. The specific description-based IGST entry for drugs and medicines under Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) applies to goods falling under Chapter 30 or any other chapter. This specific entry prevails over the general chapter-based entries for inorganic and organic chemicals. Imports for testing or research do not alter an API's character as a drug. IGST is chargeable at 5%, unless the goods fall within the nil-rated entry for drugs or medicines listed in Annexure I.
Bulk drugs and active pharmaceutical ingredients imported under Chapters 28 or 29 qualify as drugs because they are substances used as components of pharmaceutical products. The specific description-based IGST entry for drugs and medicines under Sl. No. 226 of Schedule I to Notification No. 9/2025-Integrated Tax (Rate) applies to goods falling under Chapter 30 or any other chapter. This specific entry prevails over the general chapter-based entries for inorganic and organic chemicals. Imports for testing or research do not alter an API's character as a drug. IGST is chargeable at 5%, unless the goods fall within the nil-rated entry for drugs or medicines listed in Annexure I.
Note: It is a system-generated summary and is for quick reference only.